Komodo Health Launches National Drug Projections: A Game-Changer for Healthcare Market Insights
San Francisco, CA—October 17, 2024
In a significant advancement for healthcare analytics, Komodo Health has unveiled its latest product, National Drug Projections. This innovative tool aims to revolutionize how healthcare organizations access and interpret data on pharmacy and medical benefit drugs, providing enhanced visibility into prescription trends across more than 10,000 therapies.
National Drug Projections equips users with real-time intelligence on critical market metrics, such as prescription volumes, units dispensed, and new patient initiations. By harnessing a wealth of de-identified data sourced from Komodo’s comprehensive Healthcare Map™—which encompasses Medicare and commercial claims as well as health records from over 300 million individuals—this new offering promises to empower healthcare and life sciences teams to make informed decisions about drug portfolio performance and future prospects.
Paul Gurney, Senior Vice President of Data Product at Komodo Health, emphasized the value of this solution: “National Drug Projections delivers actionable intelligence and a precise view on market dynamics to help Life Sciences companies make smarter decisions. With robust and up-to-date projections, companies can track competitive performance, proactively adjust their strategies, optimize resource allocation, and better navigate market uncertainties—ultimately helping maximize market share and drive growth in a fast-evolving landscape.”
National Drug Projections stands out as the most comprehensive market solution, displaying insights into both pharmacy benefit (including retail and specialty) and medical benefit drugs. Users can easily compare different medications—whether they are brands, biosimilars, or generics—enabling swift identification of market opportunities. Customizable reports provide clarity on projected versus observed values and include critical confidence intervals to guide decision-making.
The tool can be utilized as a standalone product or integrated into Komodo’s existing MapLab platform, ensuring accessibility for teams of varying data expertise. Within minutes, users can generate insights through a real-time dashboard, enriched with multiple variables and visualizations.
As the healthcare landscape grows increasingly complex, Komodo Health’s commitment to delivering actionable data solutions will also expand. Future enhancements to the National Drug Projections product suite are planned, including IC-grade, subnational, and indication-based projections set for rollout throughout 2025.
For more information about Komodo Health and its latest offerings, visit Komodohealth.com.
With the launch of National Drug Projections, Komodo Health is positioning itself at the forefront of healthcare analytics, enabling organizations to make data-driven decisions that can lead to improved patient outcomes and more strategic resource allocation.
